2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
Our 2023 research impact report
Our recent research impact report determines and highlights the impact our research funding has had on the Parkinson’s research field.
A biomarker for Parkinson’s?
New research from an international consortium led by the Michael J Fox Foundation has highlighted a potential biological biomarker for Parkinson’s.
A new case for GCase
Low levels of a protein called GCase is associated with an increased risk of developing Parkinson’s. New understandings of the role of GCase could help to further explain other biological processes observed in the condition.
New clinical trials targeting the LRRK2 gene
LRRK2 is a protein that becomes hyperactive in some people with Parkinson’s, and this is believed to be involved in the progression of their Parkinson’s.
Marking World Parkinson’s Day – tell us your story
Cure Parkinson’s has always had the unwavering belief that people living with Parkinson’s are key to finding the cure – and on World Parkinson’s Day we want to hear your story